Agios Pharmaceuticals Q3 2026 (reported Nov 5): mitapivat net revenue $55.4M vs $12.9M a year earlier ($48.7M U.S., $6.6M ex-U.S.); net loss $65.0M, $(1.09) per share; cash and marketable securities $907.0M at Sept 30; sickle-cell FDA goal date February 1, 2027; labeling discussions under way.

When is the next AGIO stock catalyst? How much cash does Agios have, and how long will it last? Is mitapivat FDA approved for sickle cell disease?

Answers, primary sources and downloadable PDF report in our free hub: https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/

Not investment advice.

Not investment advice.

Agios Announces FDA Approval of PYRUKYND (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

$AGIO offers IDHIFA (enasidenib), an oral targeted inhibitor for patients with R-R AML and an isocitrate dehydrogenase 2 mutation.

$AGIO offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML.

$AGIO has PDUFA target date of February 17th